Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480374 · ClinicalTrials.gov registry record · Phase 1
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
A Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Imunon.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT02480374 is a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by Imunon. The registered enrollment target is 18 participants, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02480374, a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
Conditions Studied
Interventions
- BIOLOGICAL IMNN-001
Study Locations (4)
Alabama
- University of Alabama Birmingham Cancer Center - Birmingham
Missouri
- Washington Univ. in St. Louis/Barnes Jewish Hospital - St Louis
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Wisconsin
- Medical College of Wisconsin/Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02480374
The ClinicalTrials.gov registry entry for NCT02480374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMNN-001 is the first listed.
NCT02480374 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Missouri, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT02480374 about?
NCT02480374 is a clinical study titled "Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer". This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
What is the current status of trial NCT02480374?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-09. Estimated completion is 2017-05.
What conditions does trial NCT02480374 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT02480374?
The interventions under investigation include: IMNN-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02480374?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02480374 being conducted?
This trial has 4 study locations across Alabama, Missouri, Oklahoma, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.